Video

Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia

Author(s):

Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Elias Jabbour, MD, MD Anderson Cancer Center

Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment